Access cutting-edge advanced solid tumors treatment through this clinical trial at a research site in Minneapolis. Study-provided care at no cost to qualified participants.
Access advanced solid tumors specialists in Minneapolis at no cost
This study follows strict safety protocols and ethical guidelines
All study-related advanced solid tumors treatment provided free
This is a first-in-human Phase 1/2, non-randomized, multi-centre, open-label clinical study designed to investigate safety, tolerability, PK, and preliminary anti-tumour activity of \[225Ac\]-FPI-1434 (radioimmuno-therapeutic agent) in patients with solid tumours that demonstrate uptake of \[111In\]-FPI-1547 (radioimmuno-imaging agent), and to establish the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of repeat doses of \[225Ac\]-FPI-1434 Injection in patients with sol
Sponsor: Fusion Pharmaceuticals Inc.
Check if you qualify for this advanced solid tumors clinical trial in Minneapolis, MN
If you're searching for advanced solid tumors treatment options in Minneapolis, MN, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Minneapolis research site is actively enrolling participants for this clinical trial. You'll receive care from experienced advanced solid tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.